current capabilities and services to encompass the end-to-end synthesis of mRNA vaccines in order to fulfill the current and future enormous demand for mRNA production capability and capacity.
Wisenberg expressed optimism over the company’s progress and quality services. He said, “Our vision is to be a trusted CDMO partner to the biopharma industry that helps save the lives of patients worldwide. We are now in full flight with an unfettered ability to provide superior development and manufacturing services. With the current global pandemic, we have seen the need to develop fast, innovative life-saving medicines with world class science and superior quality to our partnered clients. This is at the core of the BioCina team’s capability, experience and passion”. He added, “BioCina has a strategic focus and significant investment in mRNA process development and manufacturing for vaccines and therapeutics to support solutions using this mRNA platform for our clients.”
Stephen Patterson, Minister for Trade and Investment, applauded BioCina’s decision to expand its Adelaide facility to incorporate end-to-end mRNA vaccine manufacturing. Minister Patterson “The State Government is committed to putting the health and medical industries sector at the forefront of South Australia’s economic growth, as one of our nine key sectors. Our sector plan looks forward to 2030 with a target to more than double the HMI economic contribution to South Australia, increasing its value from $2.3 billion to $5 billion”. He added, “As Australia’s leading CDMO focused on delivering critical mRNA manufacturing capabilities, we are delighted to welcome BioCina formally to Adelaide as a flagship of the national mRNA landscape.”
